International pharmaceutical cooperation should begin with evidence that another party can verify independently. Public regulator records can provide useful signals about a manufacturer, product and market connection—but only if the record is read within its date, scope and legal context.
1. The official source
The public document used for this review is titled Liste des médicaments enregistrés à Madagascar and is dated 16 September 2025. The register identifies product names, codes, active ingredients, presentations, manufacturers and laboratories. [1]
2. The three Hainan Hailing entries identified
| Public product code | Active ingredient and presentation stated in the register | Manufacturer/laboratory name shown |
|---|---|---|
| 40787 | Amoxicillin plus potassium clavulanate, 1 g/0.2 g, powder for injection, box of 10 vials | Hainan Hailing Chemipharma Corporation Ltd. |
| 40867 | Azithromycin 0.5 g, powder for injectable preparation, box of 10 vials | Hainan Hailing Chemipharma Corporation Ltd. |
| 40800 | Ceftriaxone 1 g, powder for injection, box of 10 vials | Hainan Hailing Chemipharma Corporation Ltd. |
The three records connect Hainan Hailing’s legal name with sterile injectable products in a foreign public regulatory list. They are therefore useful as dated, product-specific evidence of an overseas registration footprint.
3. What the records can support
- Hainan Hailing appears as manufacturer or laboratory for the three listed injectable products in that public register.
- The evidence is product-specific and can be checked against the official PDF and public product codes.
- The records can support an initial discussion about international registration experience and sterile injectable cooperation.
4. What the records do not prove
- They do not prove current sales, tender awards, market share or distribution coverage.
- They do not prove that every registration remains unchanged after the date of the list.
- They do not confirm available capacity, project acceptance, lead time, pricing or supply continuity.
- They do not replace product-, site- and market-specific technical, quality or regulatory due diligence.
5. How an overseas partner should use this evidence
A potential partner can use the register as a first verification point, then move through a controlled assessment: confirm the intended product and market, verify current regulatory status with the responsible local party, establish the legal and commercial roles, and review product-specific technical, quality, supply and dossier requirements after appropriate confidentiality arrangements.
Match the company name, product, presentation, code, list date and responsible authority.
Ask the responsible registration party or authority to confirm the status and any subsequent changes.
Define dosage form, target market, project stage, requested scope and expected timing.
Use an NDA and structured review for product-specific regulatory, technical, quality and commercial evidence.
Frequently asked questions
Does an entry in a medicines register mean the product is currently being sold?
No. Registration and commercial activity are different facts and must be verified separately.
Can this list prove that Hainan Hailing has international regulatory experience?
It provides dated, product-specific evidence of a public overseas registration footprint. The precise role, history and current status should still be confirmed for a proposed project.
Does the list prove that capacity is available for a new CMO or CDMO project?
No. Capacity, equipment fit, schedule, quality requirements and project acceptance require a separate product-level assessment.
Why retain the date of the official list?
Because regulatory records can change. The date defines the scope of what the document can prove and prevents historical evidence from being presented as an undated current guarantee.
What information is appropriate for first contact?
Only non-confidential facts such as dosage form, target market, project stage, requested cooperation model and expected timing. Sensitive dossiers, formulas and trade secrets should follow an NDA and controlled review.
Authoritative sources
This article is an industry perspective for general business discussion. It is not legal, regulatory or medical advice. Project requirements must be confirmed with the responsible parties and applicable authorities.